Lupin Receives US FDA Approval for Cefadroxil Capsules

BSE : 500257	NSE: Lupin	REUTERS: LUPN.BO	BLOOMBERG: LPC IN

Mumbai, 31st May 2007: Lupin Ltd., announced today that it has received approval from the US FDA for it's Abbreviated New Drug Application (ANDA) for Cefadroxil Capsules 500mg. Cefadroxil, a broad spectrum antibiotic, is used to treat infections caused by various bacteria.

Lupin's Cefadroxil Capsules are the AB-rated generic equivalent of Warner Chilcott (erstwhile) Duricef® Capsules. This approval augments the cephalosporin portfolio of the Company in the $8.7 bn broad spectrum antibiotic market in the US.

With this approval, Lupin now has 23 ANDAs approved by the US FDA.

About Lupin
Headquartered in Mumbai, Lupin Ltd. is a leading pharmaceutical company with strong research focus. It has a programme for developing New Chemical Entities. The Company has state-of-the-art R&D center in Pune. The Company is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (prils and statins) and has a notable presence in the areas of diabetology, NSAIDS and Asthma.

For the financial year ended March 2007, Lupin's Revenues and Profit after Tax were Rs.20,289 million (US$ 475 million) and Rs. 3,021 million (US$ 70 million) respectively.

For further information contact:
Raju Kane
The Source
Tel. +91 22 24901327/28
Telefax: +91 22 24901325
Mobile: +91 98200 45656
E-mail: rajukane@sourcepr.com